LakeShore Biopharma Co Ltd
LSB0.627USD
-0.163-20.68%
收盤 09/19, 16:00（美東）報價延遲15分鐘
13.02M總市值
--本益比TTM
關於 LakeShore Biopharma Co Ltd 公司
LakeShore Biopharma Co Ltd（原名 YS Biopharma Co Ltd）是一家生物製藥公司，致力於發現、開發、生產和商業化新一代傳染病和癌症疫苗和治療性生物製劑。公司的疫苗產品 YSJATM 狂犬病疫苗已實現商業化。公司還有四種處於不同臨牀開發階段的候選產品，包括 PIKA 狂犬病疫苗、PIKA 重組 COVID-19 疫苗、PIKA YS-ON-001 和 PIKA YS-HBV-001，以及四種臨牀前階段的候選產品，針對具有巨大醫療需求的 HBV、流感和癌症。此外，公司正在研究一系列處於發現階段的治療靶點、狂犬病和產品。
公司簡介
公司代碼LSB
公司名稱LakeShore Biopharma Co Ltd
上市日期Jul 30, 2021
CEOMr. Dave Chenn
員工數量573
證券類型Ordinary Share
年結日Jul 30
公司地址Building No. 2, 38 Yongda Road
城市BEIJING
上市交易所NASDAQ Capital Market Consolidated
國家China
郵編102629
電話
網址https://www.ysbiopharm.com/
公司代碼LSB
上市日期Jul 30, 2021
CEOMr. Dave Chenn
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Mr. Gang Li
Mr. Gang Li
Head of Marketing and sales
Head of Marketing and sales
--
--
Dr. Stanley Yi Chang
Dr. Stanley Yi Chang
Independent Director
Independent Director
--
--
Dr. Ajit Shetty
Dr. Ajit Shetty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Thomas Xue
Mr. Thomas Xue
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月2日 週六
更新時間: 8月2日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Crystal Peak Investment Inc
51.01%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
Shao (Hui)
0.76%
Fidelity Management & Research Company LLC
0.28%
其他
12.17%
持股股東
持股股東
佔比
Crystal Peak Investment Inc
51.01%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
Shao (Hui)
0.76%
Fidelity Management & Research Company LLC
0.28%
其他
12.17%
股東類型
持股股東
佔比
Corporation
74.87%
Individual Investor
12.67%
Investment Advisor
0.36%
Investment Advisor/Hedge Fund
0.26%
Private Equity
0.13%
Hedge Fund
0.04%
其他
11.67%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
28
16.97M
69.54%
+11.06M
2025Q1
32
16.97M
88.94%
+11.13M
2024Q4
63
15.91M
83.38%
+8.88M
2024Q3
69
15.84M
83.04%
+8.47M
2024Q2
74
16.03M
84.03%
+8.50M
2024Q1
78
15.49M
82.30%
+7.79M
2023Q4
79
6.05M
65.03%
-1.81M
2023Q3
78
6.62M
71.14%
+3.69M
2023Q2
76
6.62M
71.12%
+3.57M
2023Q1
71
6.78M
73.08%
+4.90M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Apex Prospect Ltd
9.84M
51.55%
+9.84M
--
Feb 08, 2024
Zhang (Yi)
4.91M
25.73%
--
--
Feb 16, 2024
Shao (Hui)
313.64K
1.64%
+108.76K
+53.09%
Jun 30, 2024
Fidelity Management & Research Company LLC
116.51K
0.61%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
75.18K
0.39%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
140.43K
0.74%
--
--
Mar 31, 2025
Superstring Capital Management LP
30.79K
0.16%
--
--
Mar 31, 2025
Barclays Bank PLC
24.76K
0.13%
--
--
Mar 31, 2025
Citadel Advisors LLC
10.59K
0.06%
+10.59K
--
Mar 31, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
公告日期
類型
比率
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
